CORNELL UNIVERSITY STUDY REPORTS IMPROVED WOUND HEALING WITH LIFECELL PRODUCT; Wound Contraction Decreased and Cosmetic Appearance Improved.THE WOODLANDS, Texas--(BUSINESS WIRE)--March 28, 1996--LifeCell today reported that an animal study conducted at The New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Hospital, New York Fire Fighters Wound Healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by Laboratory showed that the Company's XenoDerm processed porcine porcine /por·cine/ (por´sin) pertaining to swine. porcine pertaining to pig. See also hog (1), swine. porcine circovirus 1 a nonpathogenic virus. dermis dermis: see skin. improved wound healing through decreased wound contraction and improved cosmetic appearance. XenoDerm grafts are processed porcine dermis, an animal-derived equivalent to LifeCell's patented AlloDerm processed tissue grafts. The findings were presented by the Cornell Burn Team Group at the American Burn Association's annual meeting held in Nashville, Tennessee, last week. The Cornell study involved the assessment of XenoDerm grafts, overlaid with an autograft autograft: see transplantation, medical. from the animal, for take rate, wound contraction and cosmetic outcome. The study showed the take rate for XenoDerm grafts was equivalent to or greater than those achieved for the animal's own skin graft skin graft Autologous, donated, or surrogate skin removed from one site to cover surfaces on another region with 3rd-degree burns or traumatic tissue loss. See Split-thickness graft. Cf Artificial skin, 'Spray-on' skin. alone (93.2% vs. 90.2%, respectively). At ten weeks post-grafting, the XenoDerm-treated wounds showed statistically less contraction and significantly better cosmetic outcome than the control wound sites treated with the animal~s own skin, the current `gold' standard. According to the Cornell Burn Team, this is the first study to quantitatively demonstrate the effectiveness of any of the dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin. der·mal or der·mic adj. Of or relating to the skin or dermis. substrates which have become available in recent years. "The ability to objectively assess the performance of these products in a controlled animal model is important in qualifying new approaches to burn therapy," commented Stephen A. Livesey, M.D, Ph.D., executive vice president and chief science officer of LifeCell. "We believe that our expanded supply base for donated human skin tissue is sufficient to meet the increasing domestic demand for AlloDerm tissue grafts and cryopreserved allograft allograft: see transplantation, medical. skin," stated Paul Frison, LifeCell's president and chief executive officer. "We are developing XenoDerm grafts in anticipation of an even greater demand for our patented dermal tissue products as we expand sales into international markets." LifeCell Corporation develops and commercializes universal tissue grafts and blood cell preservation products. LifeCell's first commercial product, AlloDerm universal dermal tissue graft, is used in the treatment of third-degree burns, in periodontal surgery and in plastic and reconstructive surgery. In addition to AlloDerm and XenoDerm tissue grafts, the Company's current universal tissue graft development programs include heart valves and vascular conduits. LifeCell's product development programs also include ThromboSol, a formulation for extending the shelf-life of transfusable platelets. CONTACT: LifeCell, The Woodlands Jane Lea Hicks, 713/367-5368 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion